Oncology support drug Totect will launch later this year to target the market for cases where anthracycline chemotherapy medication has escaped into the body.
This extravasation can cause severe damage and serious complications, but Totect, which is already FDA approved, can reverse the effect without the need for additional surgery.
Clinigen and Cumberland formed their alliance last year and have already launched one drug, Ethyol.
Arrangements for the launch of Totect are similar with Cumberland to manage all marketing, promotion, and distribution while Clinigen will retain responsibility for manufacturing, regulatory and clinical management of the product.
Clinigen acquired Totect (dexrazoxane hydrochloride) this year as part of its drive in to the US and will continue to market its existing dexrazoxane products, Savene and Cardioxane, everywhere except the US.
Shaun Chilton, Clinigen’s chief executive, said working with Cumberland had allowed it to expand its dexrazoxane portfolio into the sizable US market and would give patients to access a vital emergency support therapy.
Story by ProactiveInvestors